Advertisement

Current Oncology Reports

, Volume 3, Issue 6, pp 516–522 | Cite as

The role of adjuvant monoclonal antibody therapy for breast cancer: Rationale and new studies

  • Edith A. Perez
Article

Abstract

HER2 is a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases and is involved in the growth, invasion, metastasis, and prognosis of breast cancer. The rationale for prospective trials evaluating the role of anti-HER2 monoclonal antibody therapy for patients with high-risk HER2-positive resected breast cancer is based on several factors. These include 1) the relative and absolute poor prognosis of patients with node-positive, HER2-positive breast cancer; 2) the emerging data of potential importance concerning anthracyclines as a component of adjuvant therapy for patients with HER2-positive breast cancer; 3) the role of taxanes in the management of patients with HER2-positive metastatic breast cancer; and 4) the feasibility and efficacy of molecularly targeted anti-HER2 monoclonal antibody treatment alone or in combination with chemotherapy for patients with advanced breast cancer.

Keywords

Paclitaxel Trastuzumab Metastatic Breast Cancer Monoclonal Antibody Therapy HER2 Gene Amplification 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pressman D, Korngold L: The in vivo localization of anti-Wagner osteogenic sarcoma antibody. Cancer 1953, 6:619–623.PubMedCrossRefGoogle Scholar
  2. 2.
    Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495–497.PubMedCrossRefGoogle Scholar
  3. 3.
    Nadler LM, Stashenko P, Hardy R, et al.: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980, 40:3147–3154.PubMedGoogle Scholar
  4. 4.
    Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177–182.PubMedCrossRefGoogle Scholar
  5. 5.
    Perez EA: HER-2 as a prognostic, predictive, and therapeutic target in breast cancer. Cancer Control 1999, 6:233–240. Comprehensive review regarding HER2 as a prognostic, predictive, and therapeutic target in breast cancer.PubMedGoogle Scholar
  6. 6.
    Paik S, Bryant J, Tan-Chiu E, et al.: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000, 92:1991–1998. Describes retrospective analysis of the relative value of AC vs CMF adjuvant therapy based on HER2 status.PubMedCrossRefGoogle Scholar
  7. 7.
    Yaumauchi H, Stearns V, Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001, 19:2334–2356.Google Scholar
  8. 8.
    Romond E: A randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide followed by Taxol (AC-T) to that of Adriamycin and cyclophosphamide followed by Taxol plus Herceptin (AC-T+H) in nodepositive breast cancer patients who have tumors that overexpress HER2. NSABP-B31 Trial, 2000. Accessible at http://cancertrials.nci.nih.gov. NSABP trial evaluating chemotherapy plus or minus trastuzumab as adjuvant therapy.Google Scholar
  9. 9.
    De Laurentis M, Arpino G, Massarelli E, et al.: A meta-anlysis of the interaction between Her2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC) [abstract]. Proc ASCO 2000, 19:78a.Google Scholar
  10. 10.
    Konecny G, Thomssen C, Pegram M, et al.: HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer [abstract]. Proc ASCO 2001, 20:23a.Google Scholar
  11. 11.
    Colbleigh MA, Vogel CL, Tripathy D, et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639–2648. Describes results of therapy with single-agent trastuzumab for patients with refractory breast cancer.Google Scholar
  12. 12.
    Vogel C, Cobleigh M, Tripathy D, et al.: First-line, nonhormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody) [abstract]. Proc ASCO 2000, 19:71a.Google Scholar
  13. 13.
    Vogel CL, Cobleigh M, Tripathy D, et al.: Superior outcomes with Herceptin (trastuzumab) (H) in fluorescence in situ hybridization (FISH) - selected patients [abstract]. Proc ASCO 2001, 20:22a.Google Scholar
  14. 14.
    Osoba D, Burchmore MJ, Ash M, et al.: Health related quality of life (HRQL) of patients treated with first-line single agent trastuzumab (Herceptin) for metastatic Her-2 overexpressing breast cancer (MBC) [abstract]. Proc ASCO 2000, 19:436a.Google Scholar
  15. 15.
    Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783–792. Describes results from phase III trial demonstrating increased response rate and survival by adding trastuzumab to chemotherapy.PubMedCrossRefGoogle Scholar
  16. 16.
    Seidman AD, Fornier MN, Esteva FJ, et al.: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001, 19:2587–2595. The feasibility and activity of this combination are reported.PubMedGoogle Scholar
  17. 17.
    Perez EA, Hillman DW, Stella PJ, et al.: A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast cancer. Cancer 2000, 88:124–131. Report from a phase II cooperative group trial (NCCTG) demonstrating the activity and tolerability of this combination for patients with metastatic breast cancer.PubMedCrossRefGoogle Scholar
  18. 18.
    Burris III HA, Hainsworth JD, Miranda FT, et al.: Phase II trial of Herceptin induction followed by combination therapy with paclitaxel and carboplatin: a Minnie Pearl Research Trial [abstract]. Breast Cancer Res Treat 2000, 64:26–146.Google Scholar
  19. 19.
    Slamon DJ, Patel R, Northfelt DW, et al.: Phase II study of Taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing HER2-neu proto-oncogene: a pilot study of the UCLA Oncology Research Network [abstract]. Proc ASCO 2001, 20:49a.Google Scholar
  20. 20.
    Pienkowski T, Fumoleau P, Eiermann W, et al.: Taxotere, cisplatin and Herceptin (TCH) in first-line HER2 positive metastatic breast cancer (MBC) patients: a phase II pilot study by the Breast Cancer International Research Group (BCIRG 101) [abstract]. Proc ASCO 2001, 20:70b.Google Scholar
  21. 21.
    Burnstein HJ, Kuter I, Campos SM, et al.: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001, 19:2722–2730.Google Scholar
  22. 22.
    Gelmon K, Arnold A, Verma S, et al.: Pharmacokinetics (PK) and safety of trastuzumab (Herceptin) when administered every three weeks to women. ASCO 2001, 20:69a. Report of clinical activity and pharmacokinetics of combined paclitaxel with trastuzumab administered once every 3 weeks.Google Scholar
  23. 23.
    Mass RD, Sanders C, Charlene K, et al.: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials [abstract]. Proc ASCO 2000, 19:75a.Google Scholar
  24. 24.
    Henderson IC: Adjuvant Therapy for Beast Cancer. Statement 114. Bethesda, MD: Consensus Development Conference of the National Institutes of Health; 2000. Report from CALGB 9344 demonstrating a statistical improvement in disease-free survival by the addition of paclitaxel to AC chemotherapy in the adjuvant setting.Google Scholar
  25. 25.
    Perez EA, Addo FK, Kaufman P, et al.: Phase III trial of doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with or without trastuzumab as adjuvant treatment for women with HER-2 overexpressing node positive breast cancer. N9831 protocol. Accessible at http://cancertrials.nci.nih.gov. Ongoing NCCTG (Intergroup) trial evaluating chemotherapy plus or minus trastuzumab in the adjuvant setting.Google Scholar
  26. 26.
    Perez EA: Incorporation of taxanes in the adjuvant management of patients with breast cancer, incorporating data presented at the 2000 NIH Consensus Development Conference. Adv Breast Cancer 2001, 3:2–5.Google Scholar
  27. 27.
    Gianni L, Albanell W, Eiermann G, et al.: Feasibility, pharmacology, and antitumor activity of Herceptin (H) with doxorubicin and Taxol followed by weekly Taxol (AT&T) in Women with HER2-positive advanced breast cancer (ABC) [abstract]. Proc ASCO 2001, 20:44a.Google Scholar
  28. 28.
    Nabholtz JML: Phase III randomized study of adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) versus trastuzumab, docetaxel and either carboplatin or cisplatin in women with HER2-neu-expressing node-positive or high-risk nodenegative operable breast cancer. BCIRG protocol, 2001. Accessible at http://cancertrials.nci.nih.gov Ongoing study from BCIRG evaluating chemotherapy plus or minus trastuzumab as adjuvant therapy.Google Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Edith A. Perez
    • 1
  1. 1.Division of Hematology/OncologyMayo Clinic and Mayo FoundationJacksonvilleUSA

Personalised recommendations